{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006385","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.753730+00:00","generated_at":"2026-06-18T09:45:17.268700+00:00","sec_items":["2.02","5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Corbus Q4 net loss $10.9M; COO Craig Millian departing; CRB-701 ADC licensed from CSPC","bullets":["Net loss for Q4 2022 was $10.9M ($2.61/diluted share); FY2022 net loss $42.3M ($10.15/diluted share).","Cash and investments of $59.2M as of Dec 31, 2022, expected to fund operations through Q2 2024.","COO Craig Millian resigned effective April 14, 2023 to pursue other opportunities.","Licensed CRB-701 (Nectin-4 ADC) from CSPC; Phase 1 dose escalation ongoing in China for advanced solid tumors.","CRB-601 (anti-αvβ8 mAb) IND submission scheduled for H2 2023; first patient expected by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006385","json":"https://secwatch.observer/filing/0000950170-23-006385.json","markdown":"https://secwatch.observer/filing/0000950170-23-006385.md","text":"https://secwatch.observer/filing/0000950170-23-006385.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023006385/0000950170-23-006385-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023006385/crbp-20230303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:45:17.268700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd1c618bf7d1817508f3132750b46434046e5537","claim":"Corbus Pharmaceuticals Holdings, Inc. reported the three months ended December 31, 2022 results: net income a net loss of approximately $10.9 million, EPS a net loss per diluted share of $2.61.","evidence_excerpt":"The Company reported a net loss of approximately $10.9 million, or a net loss per diluted share of $2.61, for the three months ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023006385/0000950170-23-006385-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Net income","value":"a net loss of approximately $10.9 million"},{"label":"EPS","value":"a net loss per diluted share of $2.61"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"df2584ed2c7a4adef74d6f4822350d99dcca1a73","claim":"Corbus Pharmaceuticals Holdings, Inc. reported the year ended December 31, 2022 results: net income a net loss of approximately $42.3 million, EPS a net loss per diluted share of $10.15.","evidence_excerpt":"For the year ended December 31, 2022, the Company reported a net loss of approximately $42.3 million, or a net loss per diluted share of $10.15","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023006385/0000950170-23-006385-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"a net loss of approximately $42.3 million"},{"label":"EPS","value":"a net loss per diluted share of $10.15"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"bbe5b34425","claim":"Craig Millian resigned as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc..","evidence_excerpt":"On March 3, 2023, Craig Millian, Chief Operating Officer of the Company, submitted a notice of resignation to the Company to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023006385/0000950170-23-006385-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}